肌肉脂肪含量与NASH强烈相关:病态肥胖患者的纵向研究
该纵向研究纳入病态肥胖患者,采用肝活检评估NAFLD,并通过CT腰大肌密度计算骨骼肌脂肪指数(SMFI)。结果显示肌肉脂肪含量而非肌肉质量与NASH独立强相关,且干预后SMFI下降≥11%者均实现NASH改善。
要点
- 肌肉脂肪含量与NASH独立强相关,肌肉质量与NASH无关。
- SMFI在NASH≥F2和早期NASH F0-1中均高于NAFL。
- 干预后SMFI下降≥11%的患者全部实现NASH改善。
核心结论
- 肌肉脂肪含量而非肌肉质量与NASH强烈且独立相关,且可能是NASH的标志物甚至病理生理贡献因素。
研究设计与样本
- 纵向研究,纳入病态肥胖患者,基线n=184,干预后(饮食干预n=15或减重手术n=24)共39例随访12个月。
- 通过肝活检评估NAFLD,CT腰大肌密度计算骨骼肌脂肪指数(SMFIPsoas),CT或生物电阻抗分析评估骨骼肌质量指数(SMI)。
主要发现
- NAFLD患者肌肉质量高于无NAFLD者(CT-SMI 56.8 ± 9.9 vs. 47.4 ± 6.5 cm2/m2,p <0.0001)。
- SMFIPsoas在NASH ≥F2和早期NASH F0-1中均高于NAFL(78.5 ± 23.6和73.1 ± 15.6 vs. 61.2 ± 12.6,p <0.001)。
- NASH任一核心特征(脂肪变、炎症或气球样变)评分每变化1分均与SMFIPsoas升高相关(均p <0.05)。
- SMFIPsoas与NASH的关联在多因素调整后仍高度显著(均p <0.025)。
- 干预后NASH改善(NAFLD活动评分<3或评分降低2分)在基线NASH患者(n=32)中超过75%实现(分别为n=25或n=27),且与SMFIPsoas显著下降相关(p <0.001);SMFIPsoas下降≥11%的患者全部实现NASH改善(14/14,p <0.05)。
临床怎么用
- 肌肉脂肪含量(SMFIPsoas)可作为病态肥胖患者NASH的无创评估标志物,辅助识别高危患者。
- 干预后SMFIPsoas下降≥11%与NASH改善高度相关,可作为疗效监测的潜在指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Studies exploring the relationship between muscle fat content and non-alcoholic fatty liver disease (NAFLD) are scarce. Herein, we aimed to evaluate the association of muscle mass and fatty infiltration with biopsy-assessed NAFLD in patients with obesity. METHODS: At inclusion (n = 184) and 12 months after a dietary intervention (n = 15) or bariatric surgery (n = 24), we evaluated NAFLD by liver biopsy, and skeletal muscle mass index (SMI) by CT (CT-SMI) or bioelectrical impedance analysis (BIA-SMI). We developed an index to evaluate absolute fat content in muscle (skeletal muscle fat index [SMFI]) from CT-based psoas muscle density (SMFIPsoas). RESULTS: Muscle mass was higher in patients with NAFLD than in those without (CT-SMI 56.8 ± 9.9 vs. 47.4 ± 6.5 cm2/m2, p <0.0001). There was no association between sarcopenia and non-alcoholic steatohepatitis (NASH). SMFIPsoas was higher in NASH ≥F2 and early NASH F0-1 than in NAFL (78.5 ± 23.6 and 73.1 ± 15.6 vs. 61.2 ± 12.6, p <0.001). A 1-point change in the score for any of the individual cardinal NASH features (i.e. steatosis, inflammation or ballooning) was associated with an increase in SMFIPsoas (all p <0.05). The association between SMFIPsoas and NASH was highly significant even after adjustment for multiple confounders (all p <0.025). After intervention (n = 39), NASH improvement, defined by NAFLD activity score <3 or a 2-point score reduction, was achieved in more than 75% of patients (n = 25 or n = 27, respectively) that had pre-established NASH at inclusion (n = 32) and was associated with a significant decrease in SMFIPsoas (p <0.001). Strikingly, all patients who had ≥11% reduction in SMFIPsoas achieved NASH improvement (14/14, p <0.05). CONCLUSIONS: Muscle fat content, but not muscle mass, is strongly and independently associated with NASH. All individuals who achieved a ≥11% decrease in SMFIPsoas after intervention improved their NASH. These data indicate that muscle fatty infiltration could be a potential marker for (and perhaps a pathophysiological contributor to) NASH. LAY SUMMARY: The fat content in skeletal muscles is highly reflective of the severity of non-alcoholic fatty liver disease (NAFLD) in patients with morbid obesity. In particular, muscle fat content is strongly associated with non-alcoholic steatohepatitis (NASH) and decreases upon NASH improvement. These data indicate that muscle fatty infiltration could be a marker and possible pathophysiological contributor to NASH.
引用
- Nachit M, Kwanten WJ, Thissen JP, et al. Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity. J Hepatol. 2021. PMID: 33865909. doi:10.1016/j.jhep.2021.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。